The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

It’s a sharp turn in fortune for the chief executive and company veteran who oversaw development and mass production of the ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 14:10 Hrs [IST] Pfizer ...

Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...

当地时间10月11日，美国FDA批准辉瑞（Pfizer）药品Hympavzi（marstacimab）用于常规预防或减少12岁及以上血友病A和血友病B成人和儿童患者的出血，这些患者体内不含凝血因子VIII与IX抑制剂（中和抗体）。